Cargando…
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
There is limited evidence on the clinical utility of monitoring measurable residual disease (MRD) in patients with acute myeloid leukemia treated with lower-intensity therapy. Herein, we explored the outcomes of patients treated with venetoclax and azacitidine who achieved composite complete remissi...
Autores principales: | Pratz, Keith W., Jonas, Brian A., Pullarkat, Vinod, Recher, Christian, Schuh, Andre C., Thirman, Michael J., Garcia, Jacqueline S., DiNardo, Courtney D., Vorobyev, Vladimir, Fracchiolla, Nicola S., Yeh, Su-Peng, Jang, Jun Ho, Ozcan, Muhit, Yamamoto, Kazuhito, Illes, Arpad, Zhou, Ying, Dail, Monique, Chyla, Brenda, Potluri, Jalaja, Döhner, Hartmut |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906463/ https://www.ncbi.nlm.nih.gov/pubmed/34910556 http://dx.doi.org/10.1200/JCO.21.01546 |
Ejemplares similares
-
Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia
por: Konopleva, Marina, et al.
Publicado: (2022) -
Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine
por: Pollyea, Daniel A., et al.
Publicado: (2022) -
Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations
por: Pollyea, Daniel A., et al.
Publicado: (2022) -
P525: LONG-TERM OUTCOMES OF STEM CELL TRANSPLANT IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX + HMA THERAPIES
por: Pratz, Keith, et al.
Publicado: (2023) -
P521: FINDINGS FROM AN ANALYSIS OF PATIENTS WITH MONOCYTIC AND MONOCYTIC-LIKE ACUTE MYELOID LEUKEMIA (AML), INCLUDING AML-M4 AND AML-M5, TREATED WITH VENETOCLAX (VEN) PLUS AZACITIDINE (AZA)
por: Konopleva, Marina, et al.
Publicado: (2023)